Xintela: Awaiting results in trials and discussions

Research update Q4 2023

2024-02-29

Clinical studies progressing as planned
A loan of MSEK 16.5 granted by Flerie Invest
We keep the fair value at SEK 1.30 per share

During Q4 2023, Xintela's project progressed according to plan. To meet the short-term capital requirement, the company raised a loan of SEK 16.5 million from Flerie Invest, Xintela's main owner. This satisfies the immediate capital need, but the company must find a medium-term financing plan. We therefore see a significant financial risk in the company. Xintela reported a negative cash flow of SEK 11.6 million for the quarter and had a cash balance of SEK 7.8 million at the end of the year. Despite the financial situation, we still see great potential in the company and our motivated value is significantly higher than the current market value. Recent developments have not significantly changed our risk assumptions from our first report published in December 2023. We therefore maintain our risk-adjusted motivated value of SEK 1.30 per share.

Download report (pdf)

Martin Dominique

Chief analyst

Tobias Karlsson

Analyst